Panelists discuss how PD-L1 inhibitors such as durvalumab and sasanlimab represent a promising frontier in non–muscle-invasive bladder cancer (NMIBC) treatment. These immunotherapies work by ...

Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the ...

Panelists examine disease heterogeneity in NMIBC and discuss a balanced treatment approach that prioritizes patient quality of life and surgery effectiveness.

Hear insights from experts on key trial data presented at ASCO GU 2025. In this video, Urology Times® highlights 5 interviews on key trial data presented at the 2025 American Society of Clinical ...

The triplet regimen of cabozantinib, nivolumab, and ipilimumab improved PFS in aRCC patients but did not enhance OS compared to the doublet regimen. Patients receiving the triplet regimen experienced ...

Dose-dense MVAC plus nivolumab achieved an 84% metastases-free rate in muscle-invasive bladder cancer patients. Patients were stratified into active surveillance or intervention groups based on ...

“There has been rapid uptake of PSMA PET staging since FDA approval in 2020, with 70% of unfavorable intermediate risk or higher patients undergoing PSMA PET in the Veteran’s Health Administration ...

Belzutifan is conditionally approved in the EU for VHL disease-associated tumors and advanced clear cell RCC after prior therapies. The LITESPARK-004 trial reported a 49% objective response rate in ...

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

The MHRA has accepted the marketing authorization application for Anktiva combined with BCG for BCG-unresponsive NMIBC with CIS in the UK. Anktiva received FDA approval in the US in April 2024, and ...

“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD. In this video, Laurence Albiges, MD, PhD, shares final results from the phase 3 ...